Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Share-based Compensation (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Share-based Compensation for 6 consecutive years, with $25.6 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 216.33% to $25.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.8 million through Dec 2025, up 26.2% year-over-year, with the annual reading at $41.8 million for FY2025, 26.2% up from the prior year.
  • Share-based Compensation hit $25.6 million in Q4 2025 for Lyell Immunopharma, up from $5.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $25.6 million in Q4 2025 to a low of $5.0 million in Q2 2025.
  • Historically, Share-based Compensation has averaged $13.3 million across 5 years, with a median of $12.9 million in 2021.
  • Biggest five-year swings in Share-based Compensation: crashed 53.91% in 2023 and later surged 216.33% in 2025.
  • Year by year, Share-based Compensation stood at $21.2 million in 2021, then fell by 13.29% to $18.4 million in 2022, then plummeted by 53.91% to $8.5 million in 2023, then decreased by 4.49% to $8.1 million in 2024, then soared by 216.33% to $25.6 million in 2025.
  • Business Quant data shows Share-based Compensation for LYEL at $25.6 million in Q4 2025, $5.2 million in Q3 2025, and $5.0 million in Q2 2025.